Health Care & Life Sciences » Biotechnology | Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Progenics Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Federated Kaufmann Fund
6,816,997
8.13%
-3,123,104
0.79%
06/29/2018
iShares Core S&P Small Cap ETF
4,553,975
5.43%
1,290
0.08%
09/06/2018
Eagle Small Cap Growth Fund
3,948,024
4.71%
285,906
0.54%
06/29/2018
SPDR S&P Biotech ETF
2,575,524
3.07%
6,627
0.34%
09/06/2018
Vanguard Total Stock Market Index Fund
1,793,325
2.14%
0
0%
07/31/2018
iShares Russell 2000 ETF
1,552,456
1.85%
-828
0.03%
09/06/2018
Fidelity Select Biotechnology Portfolio
1,103,848
1.32%
0
0.09%
07/31/2018
iShares Nasdaq Biotechnology ETF
976,081
1.15%
-12,768
0.08%
09/06/2018
Vanguard Extended Market Index Fund
966,913
1.14%
23,500
0.01%
07/31/2018
PowerShares S&P Small Cap Health Care Portfolio
950,242
1.12%
60,423
0.59%
09/05/2018

About Progenics Pharmaceuticals

View Profile
Address
One World Trade Center
New York New York 1000
United States
Employees -
Website http://www.progenics.com
Updated 07/08/2019
Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.